Last reviewed · How we verify
NCT07065383: Re-CHARM
Rebalancing the Fat Content of the Heart and Muscles
NA trial testing Semaglutide administration plus dietary counselling and physical activity encouragement in Diabetes Mellitus Type 2 in 60 participants. Currently enrolling.
31 July 2028
Quick facts
| Lead sponsor | University of Aberdeen |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 60 |
| Start date | 1 August 2025 |
| Primary completion | 31 July 2028 |
| Estimated completion | 31 July 2028 |
Drugs / interventions tested
- Semaglutide administration plus dietary counselling and physical activity encouragement — full drug profile →
- Semaglutide plus a personalised and supervised program of resistance and endurance training — full drug profile →
Conditions studied
- Diabetes Mellitus Type 2 — all drugs for Diabetes Mellitus Type 2 →
Sponsor
University of Aberdeen
Who can join
Adults 20 to 75, any sex, with Diabetes Mellitus Type 2. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Traditional diabetes therapies focus on improving blood sugar control. However, many studies show that this may not be enough. New treatments focusing on weight loss have heralded better results. One of these treatments is Semaglutide and the investigators wish to examine its effects further in this study. The investigators propose to investigate what happens to the fat inside the heart and the leg muscles.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07065383
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diabetes Mellitus Type 2
Currently open trials in the same condition.
- NCT07011147 — Primary Care Pragmatic, Real World Experience for Automated Insulin Delivery · NA · recruiting
- NCT07420634 — Multilevel Ecological and COM-B Determinants of Medication Adherence in Adults With Diabetes · recruiting
- NCT07114822 — HOPE Intervention for Fitness · NA · recruiting
- NCT07245082 — Patients With Type 2 Diabetes · recruiting
- NCT07124923 — Continuous Care Intervention in Primary Care to Improve Type 2 Diabetes Control in Terres de l'Ebre, Catalonia · NA · recruiting
Other University of Aberdeen trials
Trials by the same sponsor.
- NCT07070765 — Sodium-glucose Transporter Type 2 Inhibition in Anthracycline-related Cardiotoxicity · NA · not yet recruiting
- NCT06735573 — Protein, Sarcopenic Obesity, and COPD · not yet recruiting
- NCT06714656 — Drivers and Barriers for Adopting Healthy and Sustainable Food Swaps in Young · NA · recruiting
- NCT06721312 — Continuous Heart Rate Variability Monitoring in Doctors; Understanding Patterns of Stress and Recovery and Their Relatio · recruiting
- NCT06661044 — Understanding the Benefits of Dietary Fibre Supplementation in Patients With Prostate Cancer · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07065383 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Aberdeen
- Last refreshed: 15 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07065383.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing